Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Bone; Disorder, Development and Growth
Interventions: Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Pain, Postoperative
Interventions: Transdermal Lidocaine Patch, Transdermal Hydrocolloid Placebo Patch; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 59 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lung Cancer, Non-Small Cell
Interventions: Collection of tumor and blood samples; Procedure
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Park Ridge, Illinois • St Louis, Missouri + 1 more

Conditions: Atopic Dermatitis
Interventions: topical desonide hydrogel 0.05%; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 3 Months and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma
Interventions: Endoscopic Eradication Therapy; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 30
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 25 more

Conditions: Cancer of the Liver, Liver Cancer, Neoplasms, Liver
Interventions: Microwave Ablation; Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Loma Linda, California • Los Angeles, California • Sylmar, California + 3 more

Conditions: Arterial Occlusion, Cardiovascular Diseases, Atherosclerosis, Hematoma, Anticoagulant-induced Bleeding, Coronary Artery Disease
Interventions: Statseal with TR Band, TR band only; Device
Lead sponsor: VA Long Beach Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 8 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Malignant Solid Neoplasm, Hepatocellular Carcinoma
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta; Other · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Diagnosis of Peripheral Lung Nodules
Interventions: Images acquired by needle-based Confocal Laser Endomicroscopy (nCLE); Device
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute and Chronic Non-radicular LBP
Interventions: Lidoderm®; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 7
States / cities: Phoenix, Arizona • Mill Valley, California • Weston, Florida + 4 more

Conditions: Total Knee Arthroplasty
Interventions: NEUROCUPLE™ Patch, Placebo Patch; Device
Lead sponsor: nCap Medical; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Peripheral Vascular Diseases
Interventions: riferminogene pecaplasmid, Placebo (for riferminogene pecaplasmid); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Dermatitis, Allergic Contact
Interventions: Patch Test; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Mineola, New York • Cincinnati, Ohio

Conditions: Lung Cancer, Pulmonary Nodule
Interventions: Ion Endoluminal System; Device
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Winchester, Virginia

Conditions: Prenatal Stress
Interventions: Mothers and Babies (MB) Course, Just in Time Intervention (JITI) Content, Biostamp nPoint Device; Behavioral · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Brain Cancer
Interventions: PET scan, C-Choline; Device · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: h-Patch; Device
Lead sponsor: Valeritas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostate Cancer
Interventions: Transdermal Estradiol; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 6
States / cities: Freehold, New Jersey • Hamilton, New Jersey • Morristown, New Jersey + 2 more

Conditions: Peripheral Artery Disease, Peripheral Vascular Disease
Interventions: Astron Stents, Pulsar Stents; Device
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 33
States / cities: Fremont, California • New Haven, Connecticut • Washington D.C., District of Columbia + 29 more

Conditions: Refractory Multiple Myeloma
Interventions: Tivantinib, Diagnostic laboratory biomarker analysis, Questionnaire administration, Quality-of-life assessment; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atrial Fibrillation
Interventions: Convergence Of Epicardial And Endocardial RF Ablation; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Huntsville, Alabama • Washington D.C., District of Columbia + 5 more

Conditions: Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions: Adjuvant Therapy, Aprepitant, Carboplatin, Cisplatin, Dexamethasone, Granisetron Transdermal Patch, Management of Therapy Complications, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Hinsdale, Illinois • Providence, Rhode Island

Conditions: Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction, Cardiovascular Disease
Interventions: Leuprolide acetate, Estradiol, Medroxyprogesterone, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Aurora, Colorado • Boulder, Colorado

Search by objective public record fields.

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

The OBstetric Lidocaine Patch (OBLido) Trial

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

Ablation Confirmation Study

Comparing TR Band to Statseal in Conjunction With TR Band II

Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors

nCLE For Diagnosis Of Peripheral Lung Nodules By Robotic Navigational Bronchoscopy

Topical Lidocaine Patch in Low Back Pain

NEUROCUPLE™ in TKA Patients to Enhance Pain Management

Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions

Cutaneous and Systemic Reactions to Metal Implants

A Retrospective Multicenter Review to Evaluate the Performance of the Ion Endoluminal System in Sampling Pulmonary Lesions

Promoting Healthy Brain Development: Wellness for 2 Study

Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas

Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device

Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer

Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

CONVERGE CAP Study-For The Treatment Of Symptomatic Persistent or Long-standing Persistent AF

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women